HK1218066A1 - 延迟释放型半胱胺珠粒调配物 - Google Patents

延迟释放型半胱胺珠粒调配物 Download PDF

Info

Publication number
HK1218066A1
HK1218066A1 HK16105019.8A HK16105019A HK1218066A1 HK 1218066 A1 HK1218066 A1 HK 1218066A1 HK 16105019 A HK16105019 A HK 16105019A HK 1218066 A1 HK1218066 A1 HK 1218066A1
Authority
HK
Hong Kong
Prior art keywords
delayed release
bead formulation
release cysteamine
cysteamine bead
formulation
Prior art date
Application number
HK16105019.8A
Other languages
English (en)
Chinese (zh)
Inventor
Powell Kathlene
Muttavarapu Ramesh
Dohil Ranjan
Original Assignee
Horizon Therapeutics U.S. Holding Llc
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52019418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1218066(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics U.S. Holding Llc, The Regents Of The University Of California filed Critical Horizon Therapeutics U.S. Holding Llc
Publication of HK1218066A1 publication Critical patent/HK1218066A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Fodder In General (AREA)
HK16105019.8A 2013-06-17 2014-06-17 延迟释放型半胱胺珠粒调配物 HK1218066A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835965P 2013-06-17 2013-06-17
US61/835,965 2013-06-17
PCT/US2014/042607 WO2014204881A1 (en) 2013-06-17 2014-06-17 Delayed release cysteamine bead formulation

Publications (1)

Publication Number Publication Date
HK1218066A1 true HK1218066A1 (zh) 2017-02-03

Family

ID=52019418

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105019.8A HK1218066A1 (zh) 2013-06-17 2014-06-17 延迟释放型半胱胺珠粒调配物

Country Status (25)

Country Link
US (9) US9233077B2 (enExample)
EP (2) EP3010491A4 (enExample)
JP (1) JP6468661B2 (enExample)
KR (2) KR102466253B1 (enExample)
CN (2) CN110664780B (enExample)
AP (1) AP2015008925A0 (enExample)
AR (2) AR096628A1 (enExample)
AU (1) AU2014281702C1 (enExample)
BR (1) BR112015031417B1 (enExample)
CA (2) CA2914770C (enExample)
CL (1) CL2015003662A1 (enExample)
CU (1) CU20150178A7 (enExample)
EA (1) EA031255B8 (enExample)
HK (1) HK1218066A1 (enExample)
IL (2) IL302141A (enExample)
MX (1) MX375377B (enExample)
NI (1) NI201500177A (enExample)
NZ (1) NZ714517A (enExample)
PH (2) PH12020552266A1 (enExample)
SG (1) SG11201510126QA (enExample)
TN (1) TN2015000549A1 (enExample)
TW (1) TWI649100B (enExample)
UA (1) UA117833C2 (enExample)
WO (1) WO2014204881A1 (enExample)
ZA (1) ZA201508783B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
AR096629A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Métodos para analizar composiciones de cisteamina
US10537528B2 (en) * 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (en) * 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
WO2018093364A1 (en) * 2016-11-16 2018-05-24 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10251850B2 (en) 2017-01-11 2019-04-09 Lupin Limited Process for preparation of cysteamine bitartrate
IL300825A (en) * 2017-03-15 2023-04-01 Cerecin Inc Pharmaceutical preparations with a high drug load of medium-length triglyceride chains and methods related thereto
JPWO2023249087A1 (enExample) * 2022-06-24 2023-12-28

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4959306A (en) 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20050004075A1 (en) 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
CN1596111A (zh) 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
US6815434B2 (en) 2002-01-04 2004-11-09 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CN100391448C (zh) 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
RU2367423C2 (ru) 2003-12-19 2009-09-20 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Композиции и способы для лечения диабета
US20050209441A1 (en) 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
JP4976281B2 (ja) 2004-05-03 2012-07-18 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド 代謝を調節するための材料および方法
CA2601339A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
CA2605631A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
MX382184B (es) 2006-01-27 2025-03-13 Univ California Cisteamina recubierta entericamente, cistamina y derivados de ellas.
ES2417179T3 (es) * 2007-11-30 2013-08-06 The Regents Of The University Of California Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina
CN102006785A (zh) 2008-02-17 2011-04-06 华扩达动物科学(I.P.3)有限公司 改善虾健康的材料和方法
WO2010103365A2 (en) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
US9730899B2 (en) * 2009-03-18 2017-08-15 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
CN101653426A (zh) 2009-09-16 2010-02-24 冯利萍 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法
CN101703472B (zh) * 2009-11-09 2011-06-22 上海邦成生物科技有限公司 一种半胱胺盐酸盐制粒包衣缓释产品及其制备方法
CN102077905B (zh) 2010-12-10 2013-01-02 无锡正大畜禽有限公司 一种肠溶盐酸半胱胺包膜颗粒的生产方法
US10463611B2 (en) * 2011-06-08 2019-11-05 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
AU2012340670B2 (en) * 2011-11-22 2016-12-22 The Regents Of The University Of California Cysteamine and/or cystamine for treating ischemic injury
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella

Also Published As

Publication number Publication date
US20140370085A1 (en) 2014-12-18
IL284823A (en) 2021-08-31
US20150290139A1 (en) 2015-10-15
PH12015502783A1 (en) 2016-03-21
EP3010491A4 (en) 2016-05-18
AR128816A2 (es) 2024-06-19
EP3010491A1 (en) 2016-04-27
PH12020552266A1 (en) 2022-04-25
MX2015017366A (es) 2016-07-13
KR102281747B1 (ko) 2021-07-26
MX375377B (es) 2025-03-06
US9233077B2 (en) 2016-01-12
NZ714517A (en) 2018-10-26
US9173851B1 (en) 2015-11-03
EP3939574A1 (en) 2022-01-19
NI201500177A (es) 2016-02-15
BR112015031417B1 (pt) 2022-12-27
CA2938644C (en) 2019-08-27
TWI649100B (zh) 2019-02-01
US20160095827A1 (en) 2016-04-07
UA117833C2 (uk) 2018-10-10
US20170319513A1 (en) 2017-11-09
CA2914770C (en) 2016-09-27
CU20150178A7 (es) 2016-07-29
SG11201510126QA (en) 2016-01-28
CN105492000A (zh) 2016-04-13
CL2015003662A1 (es) 2016-08-05
TW201534357A (zh) 2015-09-16
BR112015031417A2 (pt) 2017-07-25
KR20210094140A (ko) 2021-07-28
TN2015000549A1 (en) 2017-04-06
KR102466253B1 (ko) 2022-11-10
JP2016523250A (ja) 2016-08-08
US20190298665A1 (en) 2019-10-03
AU2014281702C1 (en) 2020-05-14
US20170319512A1 (en) 2017-11-09
IL302141A (en) 2023-06-01
CN105492000B (zh) 2019-11-15
ZA201508783B (en) 2019-09-25
KR20160045053A (ko) 2016-04-26
JP6468661B2 (ja) 2019-02-13
WO2014204881A8 (en) 2016-02-18
EA201690036A1 (ru) 2016-09-30
US11090279B2 (en) 2021-08-17
US20160158170A1 (en) 2016-06-09
BR112015031417A8 (pt) 2021-06-22
EA031255B1 (ru) 2018-12-28
AU2014281702B2 (en) 2019-11-07
WO2014204881A1 (en) 2014-12-24
CA2938644A1 (en) 2014-12-24
CN110664780B (zh) 2022-09-27
AR096628A1 (es) 2016-01-20
AU2014281702A1 (en) 2015-12-10
CA2914770A1 (en) 2014-12-24
US20160331704A1 (en) 2016-11-17
US20170319514A1 (en) 2017-11-09
AP2015008925A0 (en) 2015-12-31
EA031255B8 (ru) 2019-11-29
CN110664780A (zh) 2020-01-10

Similar Documents

Publication Publication Date Title
IL284823A (en) BEAD formulation of sustained-release cystamine, methods for its preparation and use
EP3205650A4 (en) Egfr inhibitor, and preparation and application thereof
EP3186277A4 (en) Antibodies, compositions, and uses
EP3104865A4 (en) Micro-organoids, and methods of making and using the same
EP3267010A4 (en) Turbocharger
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3131853A4 (en) Composite nanomaterials and micromaterials, films of same, and methods of making and uses of same
EP3225636A4 (en) Modified styrene-butadiene copolymer, method for preparing same, and rubber composition comprising same
EP3277820A4 (en) Methods for producing modified red blood cell compositions, compositions and uses thereof
EP2978409A4 (en) Ophthalmic composition, method for preparing the same, and use of the same
EP3003297A4 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
KR101881886B1 (ko) Alk 키나제 억제제, 이의 제조방법 및 이의 용도
EP3249193A4 (en) Turbocharger
EP3034523A4 (en) Method for preparing propylene-1-butene copolymer and propylene-1-butene copolymer obtained thereby
EP3065712A4 (en) Microparticles, methods for their preparation and use
EP3205335A4 (en) Emulsion composition for aerosol preparation, and aerosol agent
EP3037431A4 (en) Vancomycin derivative, and preparation method and application thereof
EP3284926A4 (en) Turbocharger
EP3248007A4 (en) Method for the formation and use of an immunolabeling complex
EP3225627A4 (en) Tripeptide compound, preparation method therefor, and application thereof
HK1223300A1 (zh) 皮质类固醇组合物
EP3003298A4 (en) Anti-fibrogenic compounds, methods and uses thereof
EP3288542A4 (en) Compositions and methods for administering antibodies
EP3081581A4 (en) Diazoresin, photoresist composition and preparation method of photoresist composition

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: INVENTOR: FROM JEREMY ZOMS